ThermoGenesis (THMO) 10-K 22 Sep 17 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Sep. 15, 2017	Dec. 30, 2016
Document Information [Line Items]
Entity Registrant Name	CESCA THERAPEUTICS INC.
Entity Central Index Key	811,212
Trading Symbol	kool
Current Fiscal Year End Date	--06-30
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		9,946,193
Entity Public Float			$ 10,334
Document Type	10-K
Document Period End Date	Jun. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Current assets:
Cash and cash equivalents	$ 3,623,000	$ 5,835,000
Accounts receivable, net of allowance for doubtful accounts of $102,000 ($49,000 at June 30, 2016)	3,701,000	3,169,000
Inventories, net of reserves of $1,230,000 ($1,437,000 at June 30, 2016)	3,617,000	3,593,000
Prepaid expenses and other current assets	237,000	246,000
Total current assets	11,178,000	12,843,000
Equipment, net	2,330,000	2,962,000
Goodwill	13,195,000	13,195,000
Intangible assets, net	20,165,000	20,821,000
Other assets	64,000	78,000
Total assets	46,932,000	49,899,000
Current liabilities:
Accounts payable	1,601,000	2,648,000
Accrued payroll and related expenses	385,000	449,000
Deferred revenue	597,000	783,000
Related party payable	606,000
Other current liabilities	1,331,000	1,662,000
Total current liabilities	4,520,000	5,542,000
Long term debt-related party	3,500,000
Derivative obligations	730,000	670,000
Convertible debentures, net		2,489,000
Noncurrent deferred tax liability	6,968,000	7,641,000
Other noncurrent liabilities	377,000	1,284,000
Total liabilities	16,095,000	17,626,000
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value; 2,000,000 shares authorized, none issued and outstanding at June 30, 2017 and 2016
Common stock, $0.001 par value; 350,000,000 shares authorized; 9,915,868 issued and outstanding (3,010,687 at June 30, 2016)	10,000	3,000
Paid in capital in excess of par	216,222,000	188,569,000
Accumulated deficit	(185,357,000)	(156,262,000)
Accumulated other comprehensive loss	(38,000)	(37,000)
Total stockholders’ equity	30,837,000	32,273,000
Total liabilities and stockholders’ equity	$ 46,932,000	$ 49,899,000

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Accounts Receivable, Allowance for Doubtful Accounts	$ 102,000	$ 49,000
Inventories, Reserves	$ 1,230,000	$ 1,437,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	2,000,000	2,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	350,000,000	350,000,000
Common stock, shares issued (in shares)	9,915,868	3,010,687
Common stock, shares outstanding (in shares)	9,915,868	3,010,687

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Net revenues	$ 14,525,000	$ 11,929,000
Cost of revenues	8,686,000	9,185,000
Gross profit	5,839,000	2,744,000
Expenses:
Sales and marketing	1,531,000	2,148,000
Research and development	2,497,000	3,230,000
General and administrative	11,051,000	8,231,000
Total operating expenses	15,079,000	13,609,000
Loss from operations	(9,240,000)	(10,865,000)
Other income (expense):
Interest expense	(10,668,000)	(1,864,000)
Amortization of debt discount	(9,851,000)	(6,127,000)
Fair value change of derivative instruments	(60,000)	3,395,000
Registration rights liquidated damages		(1,100,000)
Loss on cashless exercise of warrants		(1,039,000)
Loss on extinguishment of debt		(795,000)
Loss on modification of Series A warrants		(149,000)
Other income and (expenses)	51,000	(44,000)
Total other income (expense)	(20,528,000)	(7,723,000)
Loss before benefit for income taxes	(29,768,000)	(18,588,000)
Benefit for income taxes	673,000
Net loss	(29,095,000)	(18,588,000)
COMPREHENSIVE LOSS
Net loss	(29,095,000)	(18,588,000)
Other comprehensive loss:
Foreign currency translation adjustments	(1,000)	(32,000)
Comprehensive loss	$ (29,096,000)	$ (18,620,000)
Per share data:
Basic and diluted net loss per common share (in dollars per share)	$ (3.27)	$ (7.57)
Weighted average common shares outstanding – Basic and diluted (in shares)	8,904,508	2,455,548

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($)	Series B Warrant [Member]Common Stock [Member]	Series B Warrant [Member]Additional Paid-in Capital [Member]	Series B Warrant [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Jun. 30, 2015				2,027,386
Balance at Jun. 30, 2015				$ 2,000	$ 172,579,000	$ (137,674,000)	$ (5,000)	$ 34,902,000
Stock-based compensation expense, net of stock surrenders (in shares)				11,577
Stock-based compensation expense, net of stock surrenders					710,000			710,000
Discount due to beneficial conversion features					7,262,000			7,262,000
Discount due to warrants					4,434,000			4,434,000
Issuance of common shares in financing (in shares)				735,294
Issuance of common shares in financing				$ 1,000	2,463,000			2,464,000
Issuance of common shares for exercise of Series B warrants (in shares)	231,710
Issuance of common shares for exercise of Series B warrants		$ 1,097,000	$ 1,097,000
Common stock issued to directors in lieu of cash compensation (in shares)				4,720
Common stock issued to directors in lieu of cash compensation					24,000			24,000
Foreign currency translation adjustments							(32,000)	(32,000)
Net loss						(18,588,000)		(18,588,000)
Balance at Jun. 30, 2016				$ 3,000	188,569,000	(156,262,000)	(37,000)	32,273,000
Balance (in shares) at Jun. 30, 2016				3,010,687
Stock-based compensation expense, net of stock surrenders (in shares)				125,368
Stock-based compensation expense, net of stock surrenders					1,445,000			1,445,000
Shares issued upon debt conversion (in shares)				6,102,941
Shares issued upon debt conversion				$ 6,000	23,897,000			23,903,000
Issuance of common shares in financing (in shares)				600,000
Issuance of common shares in financing				$ 1,000	2,091,000			2,092,000
Common stock issued to directors in lieu of cash compensation (in shares)				5,463
Common stock issued to directors in lieu of cash compensation					16,000			16,000
Common stock issued to employees for prior year bonus (in shares)				71,409
Common stock issued to employees for prior year bonus					204,000			204,000
Foreign currency translation adjustments							(1,000)	(1,000)
Net loss						(29,095,000)		(29,095,000)
Balance at Jun. 30, 2017				$ 10,000	$ 216,222,000	$ (185,357,000)	$ (38,000)	$ 30,837,000
Balance (in shares) at Jun. 30, 2017				9,915,868

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Cash flows from operating activities:
Net loss	$ (29,095,000)	$ (18,588,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	830,000	1,168,000
Stock-based compensation expense	1,461,000	742,000
(Recovery of) reserve for excess and slow-moving inventories	(203,000)	566,000
Amortization of debt discount	9,851,000	6,127,000
Amortization of debt issue costs	160,000	800,000
Change in fair value of derivative	60,000	(3,395,000)
Deferred income tax benefit	(673,000)
Non-cash accrued interest	10,373,000	1,031,000
Loss on disposal of equipment	176,000
Impairment of intangible asset	310,000
Loss on cashless exercise of warrants		1,039,000
Loss on extinguishment of debt		795,000
Loss on modification of Series A warrants		149,000
Net changes in operating assets and liabilities:
Accounts receivable	(522,000)	1,956,000
Inventories	615,000	375,000
Prepaid expenses and other assets	24,000	(86,000)
Accounts payable	(1,062,000)	(2,420,000)
Related party payable	606,000
Accrued payroll and related expenses	(63,000)	(256,000)
Deferred revenue	(187,000)	148,000
Other current liabilities	26,000	160,000
Other noncurrent liabilities	98,000	64,000
Net cash (used in) operating activities	(7,215,000)	(9,625,000)
Cash flows from investing activities:
Capital expenditures	(375,000)	(710,000)
Net cash (used in) investing activities	(375,000)	(710,000)
Cash flows from financing activities:
Gross proceeds from convertible debentures		18,000,000
Proceeds from long term debt-related party	3,500,000
Payment of financing cost – convertible debentures		(961,000)
Repayment of convertible debentures		(6,444,000)
Payment to extinguish derivative obligations		(159,000)
Payments on capital lease obligations	(84,000)	(67,000)
Proceeds from issuance of common stock, net	2,092,000	2,463,000
Repurchase of common stock	(134,000)	(8,000)
Net cash provided by financing activities	5,374,000	12,824,000
Effects of foreign currency rate changes on cash and cash equivalents	4,000	(11,000)
Net (decrease)increase in cash and cash equivalents	(2,212,000)	2,478,000
Cash and cash equivalents at beginning of year	5,835,000	3,357,000
Cash and cash equivalents at end of year	3,623,000	5,835,000
Supplemental non-cash financing and investing information:
Common stock issued for payment of convertible debenture and interest	23,903,000
Transfer of equipment to inventories	625,000
Derivative obligation related to issuance of warrants		4,282,000
Retirement of equipment		$ 1,109,000

Note 1 - Description of Busines

Note 1 - Description of Business and Basis of Presentation	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Organization and Basis of Presentation Cesca Therapeutics Inc. (the “Company” or “Cesca”) develops and markets integrated cellular therapies and delivery systems that advance the safe and effective practice of regenerative medicine. Cesca’s product pipeline includes automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. On March 4, 2016, one 1 twenty 20 no 350,000,000. Liquidity On July 7, 2017, 20% one $1.0 14 On March 6, 2017, 5 June 30, 2017, $3,500,000 $5,000,000 The Company has drawn down an additional $1,500,000 June 30, 2017 Boyalife Investment Fund II, Inc. is a wholly owned subsidiary of Boyalife Group Inc., which is owned and controlled by the Company’s Chief Executive Officer and Chairman of the Board. On September 13, 2017, $5.0 $10.0 On August 22, 2016, February 2016 $23,903,000 February 2016 6,102,941 On August 3, 2016, 600,000 $4.10 The net proceeds to the Company from the sale and issuance of the shares, after deducting the offering expenses borne by the Company, were $2,092,000. At June 30, 2017, $3,623,000 $6,658,000. June 30, 2017 $185,357,000. Based upon the additional funds available to draw down under the amended Credit Agreement, the Company’s cash balance, historical trends, expected outflows and projections for revenues, management believes it will have sufficient cash to provide for its projected needs to maintain operations and working capital requirements for at least the next 12 Principles of Consolidation The consolidated financial statements include the accounts of Cesca Therapeutics Inc. and its wholly owned subsidiaries, ThermoGenesis Corp. (“ThermoGenesis”), TotipotentRX Cell Therapy, Pvt. Ltd. and TotipotentSC Scientific Product Pvt. Ltd. All significant intercompany accounts and transactions have been eliminated upon consolidation. After completion of the acquisition of SynGen by ThermoGenesis on July 7, 2017, no

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not Revenue Recognition Revenues from the sale of the Company’s products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company generally ships products F.O.B. shipping point. There is no The Company’s sales are generally through distributors. There is no not may not Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to 21 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues. Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three may $46,000 $104,000 June 30, 2017 2016, not Foreign Currency Translation The Company’s reporting currency is the US dollar. The functional currency of the Company’s subsidiaries in India is the Indian rupee (INR). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not $1,000 $32,000 June 30, 2017 2016, Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not three ten not For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not ASC ”) 350, not 50 The Company performed a quantitative assessment as of April 1, 2017 June 30, 2017 no For the definite-lived intangible assets other than the covenants not no may not no no $310,000 not June 30, 2017 Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Other observable inputs other than Level 1 not Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3 Accounts Receivable and Allowance for Doubtful Accounts The Company’s receivables are recorded when billed and represent claims against third may Inventories Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first first not third As a result, actual demand may may Equipment, Net Equipment consisting of office furniture, computer, machinery and equipment is recorded at cost less accumulated depreciation and amortization. Repairs and maintenance costs are expensed as incurred. Depreciation for office furniture, computer, machinery and equipment is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight line method over their estimated useful lives or the remaining lease period, whichever is shorter. When equipment is sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and the impact of any resulting gain or loss is recognized within Other income and (expenses) in the consolidated statement of operations for the period. Warranty The Company provides for the estimated cost of product warranties at the time revenue is recognized. The Company’s warranty obligation is calculated based on estimated product failure rates, material usage and estimated service delivery costs incurred in correcting a product failure. Debt Issue Costs The Company amortizes debt issue costs to interest expense over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Debt Discount The Company amortizes debt discount over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Such amortized cost is included with the other income (expense) in the accompanying consolidated statements of operations. Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may first Stock-Based Compensation The Company has three 9. Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not not Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award’s vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that corresponded to the expected term of the options. Expected Dividend – The Company has not not zero Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero Estimated Forfeitures – When estimating forfeitures, the Company considers voluntary and involuntary termination behavior as well as analysis of actual option forfeitures. Research and Development Research and development costs, consisting of salaries and benefits, costs of clinical trials, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory, scientific and clinical affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may no A cquired In-Process Research and Development Acquired in-process research and development (“clinical protocols”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not first not not 2017 April 1, 2017. no Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred. Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company’s customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two The Clinical Development Division is devel op ing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. The Device Division is a pioneer and market leader in the development and commercialization of automated technologies for c ell-based t herapeutics and bio-processing. Income Taxes The tax years 1999 2015 no no no The Company’s estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company’s assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company’s current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not differences are expected to reverse. As the Company operates in more than one may Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company’s estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company’s pre-existing deferred tax assets. Net Loss per Share Net loss per share is computed by dividing the net loss to common stockholders by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at June 30: 2017 2016 Common stock equivalents of convertible debentures -- 3,676,471 Vested Series A warrants 404,412 404,412 Unvested Series A warrants 698,529 (1) 698,529 (1) Warrants – other 3,725,782 3,725,782 Stock options 397,388 104,378 Restricted stock units 59,694 63,566 Total 5,285,805 8,673,138 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021. Recently Adopted Accounting Standards In June 2014, No. 2014 12, Compensation - Stock Compensation (Topic 718 Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period 2014 12 2014 12 July 1, 2016. 2014 12 2014 12 not Recently Issued Accounting Standards In July 2017, No. 2017 11, Earnings Per Share (Topic 260 480 815 2017 11 may no 2017 11 December 15, 2018, 2017 11 not 2017 11 In May 2017, No. 2017 09 718 2017 09 2017 09 718. December 15, 2017, In January 2017, 2017 04 2 December 15, 2019. January 1, 2017. not 2017 04 In March 2016, 2016 09, Compensation - Stock Compensation (Topic 718 2016 09 2016 09 December 15, 2016 not 2016 09 In March 2016, No. 2016 06, Derivatives and Hedging (Topic 815 2016 06” 2016 06 December 15, 2017, December 15, 2018. not In February 2016, 2016 02, “Leases (Topic 842 2016 02 2016 02 December 15, 2018 not 2016 02 In July 2015, No. 2015 11, Inventory: Simplifying the Measurement of Inventory not first December 15, 2016, In May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 2014 09 605, 605 35, Revenue Recognition - Construction-Type and Production-Type Contracts 2014 09 2014 09 2014 09 2014 09 two first 2014 09 second 2014 09 2014 09 2019 2015 14, Revenue from Contracts with Customers (Topic 606 August 2015 one 2014 09 2015 14 not may There have been four 2014 09, 2016 08, Principal versus Agent Considerations (Reporting Revenue Gross Versus Net) March 2016 2014 09. 2016 10, Identifying Performance Obligations and Licensing April 2016, 2014 09 2016 12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients 2014 09 approach to adopt ASU 2014 09. 2016 20, Technical Corrections and Improvements to Topic 606, December 2016, 2014 09, four

Note 3 - Intangible Assets

Note 3 - Intangible Assets	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	3. Intangible Assets Intangible assets consist of the following based on the Company’s determination of the fair value of identifiable assets acquired: As of June 30, 2017 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulate d Amortization Impairment Net Trade names 7 $ 30,000 $ 14,000 $ 16,000 Licenses 7 482,000 233,000 249,000 Customer relationships 3 443,000 443,000 -- Device registration 7 90,000 60,000 30,000 Covenants not to compete 5 955,000 645,000 $ 310,000 -- Amortizable intangible assets 2,000,000 1,395,000 310,000 295,000 Clinical protocols 19,870,000 -- 19,870,000 Total $ 21,870,000 $ 1,395,000 $ 310,000 $ 20,165,000 As of June 30, 2016 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Net Trade names 7 $ 29,000 $ 10,000 $ 19,000 Licenses 7 462,000 157,000 305,000 Customer relationships 3 424,000 335,000 89,000 Device registration 7 86,000 49,000 37,000 Covenants not to compete 5 955,000 454,000 501,000 Amortizable intangible assets 1,956,000 1,005,000 951,000 Clinical protocols 19,870,000 -- 19,870,000 Total $ 21,826,000 $ 1,005,000 $ 20,821,000 The change in the gross carrying amount is due to foreign currency exchange fluctuations. There was a $310,000 not June 30, 2017 $359,000 $438,000 June 30, 2017 2016. not not Year Ended June 30, 2018 $ 81,000 2019 81,000 2020 81,000 2021 52,000 Total $ 295,000

Note 4 - Equipment

Note 4 - Equipment	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	4. Equipment, Net Equipment consisted of the following at June 30: 2017 2016 Estimated Useful Life (years) Machinery and equipment $ 5,772,000 $ 6,604,000 2.5 - 10 Computer and software 733,000 397,000 2 - 5 Office equipment 427,000 260,000 5 - 10 Leasehold improvements 227,000 149,000 Shorter of 5 years or remaining lease term Total equipment 7,159,000 7,410,000 Less accumulated depreciation and amortization (4,829,000 ) (4,448,000 ) Total equipment, net $ 2,330,000 $ 2,962,000 Depreciation and amortization expense for the years ended June 30, 2017 2016 $408,000 $630,000,

Note 5 - Related Party Transact

Note 5 - Related Party Transactions	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	5 . Related Party Transactions Bill Payment Arrangement The Company entered into a bill payment arrangement whereby Boyalife Group Ltd. (“Payor”), the Company’s largest shareholder, agreed to pay the Company’s legal expenses payable to the Company’s attorney related to certain litigation involving SynGen Inc. (the “Bill Payment Arrangement”), although the Company remains jointly and severally liable for the payment of such legal fees. The terms of the Bill Payment Arrangement provided that the Company will reimburse Payor for any and all amounts paid by Payor in connection with the Bill Payment Arrangement under certain specified events. There is no no June 30, 2017, $606,000 Revolving Credit Agreement On March 6, 2017, $5,000,000 $500,000 March 6, 2022 ( $1,500,000 $2,000,000 June 30, 2017, $1,500,000 September 30, 2017. The Credit Agreement and the Convertible Promissory Note issued thereunder (the “Note”) provide that the principal and all accrued and unpaid interest under the Loan will be due and payable on the Maturity Date, with payments of interest-only due on the last day of each calendar year. The Loan bears interest at 22% not not 90% 10 may not 19.99% The Maturity Date of the Note is subject to acceleration at the option of the Lender upon customary events of default, which include a breach of the Loan documents, termination of operations, or bankruptcy. The Lender’s obligation to make advances under the Loan is subject to the Company’s representations and warranties in the Credit Agreement continuing to be true at all times and there being no No The Company recorded interest expense of $122,000 June 30, 2017. On September 13, 2017, No. 1 March 6, 2017, $5.0 $10.0 $10.0 Distributor Agreement and Subsequent Event On August 21, 2017, ® ® ® ® The term of the agreement is for three two Revenues During the year ended June 30, 2017, $308,000 $308,000 June 30, 2017. September 5, 2017

Note 6 - Convertible Debentures

Note 6 - Convertible Debentures	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	6 . Convertible Debentures February 2016 Financing Transaction In February 2016 $15, 000,000 735,294 $3.40 $2,500 ,000 $12,500,000 3,676,471 , and (iii) warrants to purchase 3,529,412 $8.00 five 80% August 13, 2016 June 30, 2017. On August 22, 2016, $12,500,000 $8,250,000 6,102,941 2,426,470 $11,403,000 August 22, 2016. $3,153,000 At the time of the conversion, the remaining debt discount of $9,538,000 $155,000 Thirty-Year Debenture Restructuring Transaction On August 31, 2015, $15,000,000 1,102,942 $13.60 five one 606,618 $13.60 eighteen August 31, 2015, $5,500,000 404,412 222,427 second $9,500,000 $10,000,000 August 2015. For financial reporting purposes, the net proceeds of $4,720,000 first $3,385,000 $897,000 $438,000 $0. $4,720,000 30 The Company entered into a registration rights agreement pursuant to which the Company agreed to register all of the shares of common stock then issued and issuable upon conversion in full of the Thirty-Year Debentures and all warrant shares issuable upon exercise of the Series A warrants and Series B warrants. The holders were entitled to receive liquidated damages upon the occurrence of a number of events relating to filing, getting an effective and maintaining an effective registration statement, including the failure of the Company to have such registration statement declared effective by October 26, 2015. not November 24, 2015 five $1,100,000 June 30, 2016. one $220,000 three December 31, 2015. In connection with the February 2016 $7.5 $13.60 $8.00. 91%, 1.2%, 5 0%. $149,000 June 30, 2016. Pursuant to the terms of the Consent Repayment and Release Agreement, the holders of the Series B warrants made a single, one 125,000 $159,000 This restructuring transaction occurred on February 16, 2016 $795,000 June 30, 2016. Payment $ 7,500,000 Repayment of Thirty-Year debentures (5,500,000 ) Payment of accrued liquidated damages and interest (897,000 ) Loss on modification of Series A warrants (149,000 ) Cancellation of Series B derivative obligation (159,000 ) Loss on extinguishment of debt $ 795,000 At the time of the repayment, the remaining debt discount of $4,648,000 $765,000 June 30, 2016, $4,720,000 $777,000

Note 7 - Derivative Obligations

Note 7 - Derivative Obligations	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Derivatives and Fair Value [Text Block]	7 . Derivative Obligations Series A Warrants Series A warrants to purchase 404,412 June 30, 2016. Series A June 30, 2017 June 30, 2016 Market price of common stock $ 3.17 $ 2.93 Expected volatility 110 % 99 % Contractual term (years) 3.7 4.7 Discount rate 1.66 % 1.01 % Dividend rate 0 % 0 % Exercise price $ 8.00 $ 8.00 Expected volatilities are based on the historical volatility of the Company’s common stock. Contractual term is based on remaining term of the respective warrants. The discount rate represents the yield on U.S. Treasury bonds with a maturity equal to the contractual term. The Company recorded a (loss)gain of ( $60,000 $3,395,000 June 30, 2017 2016, The following table represents the Company’s fair value hierarchy for its financial liabilities measured at fair value on a recurring basis as of June 30, 2017 2016: Balance at June 30, 2017 Level 1 Level 2 Level 3 Derivative obligation $ 730,000 $ - $ - $ 730,000 Balance at June 30, 2016 Level 1 Level 2 Level 3 Derivative obligation $ 670,000 $ - $ - $ 670,000 The following table reflects the change in fair value of the Company’s derivative liabilities for the year ended June 30, 2017: Amount Balance – July 1, 2016 $ 670,000 Change in fair value of derivative obligation 60,000 Balance – June 30, 2017 $ 730,000

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8 . Commitments and Contingencies Operating Leases The Company leases the Rancho Cordova and Gurgaon, India facilities pursuant to operating leases, which contain scheduled rent increases. The leases expire in May 2019 March 2018, one September 14, 2023. September 2019 three 2018 297,000 2019 279,000 2020 3,000 Total $ 579,000 Rent expense was $291,000 $657,000 June 30, 2017 2016, Financial Covenants Effective May 15, 2017, one not $2,000,000. June 30, 2017 August 31, 2017. Potential Severance Payments The Company’s Chief Operating Officer (“COO”) has rights upon termination under her employment agreement. The agreement provides, among other things, for the payment of twelve June 30, 2017, $320,000. Contingencies In fiscal 2016, May 4, 2017, $1,000,000 August 2016. no June 30, 2017. In the normal course of operations, the Company may June 30, 2017, may not Warranty The Company offers a warranty on all of the Company’s non-disposable products of one two Changes in the Company’s product liability which is included in other current liabilities during the period are as follows: For years ended June 30, 2017 2016 Beginning balance $ 566,000 $ 627,000 Warranties issued during the period 120,000 97,000 Settlements made during the period (93,000 ) (287,000 ) Changes in liability for pre-existing warranties during the period (5,000 ) 129,000 Ending balance $ 588,000 $ 566,000

Note 9 - Stockholders' Equity

Note 9 - Stockholders' Equity	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	9 . Stockholders’ Equity Common Stock On August 22, 2016, $12,500 ,000 $8,250 ,000 6,102,941 6 On August 3, 2016, 600,000 $4.10 $369 ,000, $2,092,000 . In July 2016, 118,288 2016 46,879 Warrants A summary of warrant activity is as follows: 2017 2016 Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted - Average Exercise Price Per Share Beginning balance 4,828,723 $ 9.37 252,620 $ 44.18 Warrants granted -- 5,238,971 $ 9.83 Warrants exercised (cashless) -- (51,712 ) $ 13.60 Warrants expired/canceled -- (611,156 ) $ 17.21 Outstanding at June 30 4,828,723 $ 9.37 4,828,723 $ 9.37 Exercisable at June 30 4,130,192 $ 9.60 600,782 $ 19.02 Equity Plans and Agreements The Company recorded stock-based compensation of $1,461,000 $742,000 June 30, 2017 2016. On May 5, 2017, 2016 2016 600,000 may June 30, 2017, 254,224 2016 The 2012 “2012 25,000 2012 100% not ten one June 30, 2017, 194 The 2006 “2006 2006 not 2016. June 30, 2017, 134,164 On July 7, 2016, may $276,000. 104,000 2006 July 26, 2016, 98,417 $266,000 July 1, 2017, July 1, 2017 eight June 30, 2017, 51,636 46,781 July 1, 2017. Upon the termination of the employment of the Company’s Chief Executive Officer (“CEO”) in November 2016 March 2017, $539,000 December 31, 2016, 72,496 79,720 $94,000 March 31, 2017 16,248 15,914 90 no On February 24, 2017, 25,000 25,000 2016 “2016 four 25% March 31, 25% June 30, 25% September 30 25% December 31 February 2017 $2.89, In December 2016, 50,000 2016 $2.91, five December 16, 2016, February 4, 2017, May 4, 2017, August 4, 2017 November 4, 2017 seven Stock Options The Company issues new shares of common stock upon exercise of stock options. The following is a summary of option activity for the Company’s stock option plans: Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at June 30, 2016 104,378 $ 14.85 Granted 318,324 $ 2.98 Forfeited/cancelled (22,814 ) $ 6.39 Expired (2,500 ) $ 18.46 Exercised -- -- Outstanding at June 30, 2017 397,388 $ 5.80 6.2 $ 69,000 Vested and Expected to Vest at June 30, 2017 376,595 $ 5.94 6.2 $ 64,000 Exercisable at June 30, 2017 242,073 $ 7.38 5.5 $ 43,000 The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of the Company’s common stock. There were no June 30, 2017 2016. On July 7, 2016, 156,100 2016 $2.86, six three seven Non-vested stock option activity for the year ended June 30, 2017, Non-vested Stock Options Weighted-Average Grant Date Fair Value Outstanding at June 30, 2016 43,107 $ 7.46 Granted 318,325 $ 2.16 Vested (185,019 ) $ 3.07 Forfeited (21,097 ) $ 3.31 Outstanding at June 30, 2017 155,316 $ 2.39 The fair value of the Company’s stock options granted for the years ended June 30, 2017 2016 2017 2016 Expected life (years) 4 5 Risk-free interest rate 1.3 % 1.5 % Expected volatility 102 % 80 % Dividend yield 0 % 0 % The weighted average grant date fair value of options granted during the years ended June 30, 2017 2016 $2.16 $5.75, At June 30, 2017, not $275,000. one June 30, 2017 2016 $572,000 $354,000. Common Stock Restricted Awards The following is a summary of restricted stock unit activity: 2017 2016 Number of Shares Weighted- Average Grant Date Fair Value Number o f Shares Weighted- Average Grant Date Fair Value Balance at June 30 63,566 $ 14.96 72,589 $ 22.40 Granted 123,417 $ 4.55 10,000 $ 2.98 Vested (125,513 ) $ 9.47 (6,120 ) $ 28.94 Forfeited (1,776 ) $ 27.05 (12,903 ) $ 41.15 Outstanding at June 30 59,694 $ 4.62 63,566 $ 14.96 In connection with the vesting of the restricted stock unit awards, the election was made by some of the employees to satisfy the applicable federal income tax withholding obligation by a net share settlement, pursuant to which the Company withheld 145 1,300 June 30, 2017 2016, As of June 30, 2017, $43,000 seven

Note 10 - Concentrations

Note 10 - Concentrations	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	10 . Concentrations One distributor had an accounts receivable balance of $1,388,000 36% $901,000 28% June 30, 2017 2016, not August 2017 $259,000 7% $620,000 19% June 30, 2017 2016, second $304,000 8% $320,000 10% June 30, 2017 2016, Revenues from a customer totaled $3,263,000 22% $2,475,000 21% June 30, 2017 2016, one $2,842,000 20% $2,797,000 23% June 30, 2017 2016, not August 2017 The following represents the Company’s revenues by product platform for the years ended June 30: 2017 2016 AXP $ 8,715,000 $ 6,932,000 BioArchive 3,318,000 2,465,000 Manual Disposables 1,195,000 1,507,000 Bone Marrow 745,000 459,000 Other 552,000 566,000 $ 14,525,000 $ 11,929,000 The Company had sales to customers as follows for the years ended June 30: 2017 2016 United States $ 6,675,000 $ 5,122,000 China 3,296,000 2,797,000 Asia – other 1,951,000 1,955,000 Europe 1,739,000 1,343,000 Other 864,000 712,000 $ 14,525,000 $ 11,929,000 The Company attributes revenue to different geographic areas based on where items are shipped or services are performed. Two suppliers accounted for 64% 20% June 30, 2017. Two 65% 21% June 30, 2016. The Company has a contract manufacturer in Costa Rica that produces certain disposables. The Company’s equipment, net of accumulated depreciation, is summarized below by geographic area: June 30, 2017 June 30, 2016 United States $ 1,559,000 $ 2,030,000 Costa Rica 322,000 367,000 India 261,000 279,000 All other countries 188,000 286,000 Total equipment, net $ 2,330,000 $ 2,962,000

Note 11 - Segment Reporting

Note 11 - Segment Reporting	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	11. Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its Chief Executive Officer and Chief Operating Officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. During the quarter ended June 30, 2017, two The Clinical Development Division is devel op ing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. The Device Division is a pioneer and market leader in the development and commercialization of automated technologies for c ell-based t herapeutics and bio-processing. The following table summarizes the operating results of the Company’s reportable segments: Year Ended June 30, 2017 Clinical Development Device Total Net revenues $ 492,000 $ 14,033,000 $ 14,525,000 Cost of revenues 466,000 8,220,000 8,686,000 Gross profit 26,000 5,813,000 5,839,000 Operating expenses 8,966,000 6,113,000 15,079,000 Operating profit (loss) $ (8,940,000 ) $ (300,000 ) $ (9,240,000 ) Depreciation and amortization $ 501,000 $ 329,000 $ 830,000 Stock-based compensation expense $ 970,000 $ 491,000 $ 1,461,000 Year Ended June 30, 2016 Clinical Development Device Total Net revenues $ 646,000 $ 11,283,000 $ 11,929,000 Cost of revenues 574,000 8,611,000 9,185,000 Gross profit 72,000 2,672,000 2,744,000 Operating expenses 8,312,000 5,297,000 13,609,000 Operating profit (loss) $ (8,240,000 ) $ (2,625,000 ) $ (10,865,000 ) Depreciation and amortization $ 644,000 $ 524,000 $ 1,168,000 Stock-based compensation expense $ 548,000 $ 194,000 $ 742,000 The Company has not

Note 12 - Income Taxes

Note 12 - Income Taxes	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	12 . Income Taxes Loss before income tax benefits was comprised of $29,005,000 $763,000 2017 $17,789,000 $799,000 2016. The reconciliation of federal income tax attributable to operations computed at the federal statutory tax rate of 34% June 30: 2017 2016 Statutory federal income tax benefit $ (10,121,000 ) $ (6,300,000 ) Unbenefited net operating losses and credits 2,281,000 3,391,000 Disallowed financing costs 6,959,000 2,607,000 State and local taxes 88,000 69,000 Other 120,000 233,000 Total income tax benefit $ (673,000 ) $ -- The deferred income tax benefit of $673,000 $559,000 2017, $157,000 2016 $402,000 2016. June 30, 2015 June 30, 2016, 2017. not not At June 30, 2017, $118,956,000 $42,922,000 2018 2037. At June 30, 2017, $1,458,000 2019 2037, $1,456,000 not Significant components of the Company’s deferred tax assets and liabilities for federal and state income taxes are as follows: June 30, 2017 June 30, 2016 Deferred tax assets: Net operating loss carryforwards $ 43,687,000 $ 41,023,000 Income tax credit carryforwards 2,419,000 2,367,000 Stock compensation 1,047,000 874,000 Other 1,124,000 1,858,000 Total deferred tax assets 48,277,000 46,122,000 Deferred tax liabilities Indefinite lived intangible assets (6,968,000 ) (7,641,000 ) Depreciation and amortization (176,000 ) (230,000 ) Total deferred tax liabilities (7,144,000 ) (7,871,000 ) Valuation allowance (48,101,000 ) (45,892,000 ) Net deferred taxes $ (6,968,000 ) $ (7,641,000 ) The valuation allowance increased by $2,209,000 2017. June 30, 2017, $215,000 In August 2016, 1986.

Note 13 - Employee Retirement P

Note 13 - Employee Retirement Plan	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Pension and Other Postretirement Benefits Disclosure [Text Block]	13 . Employee Retirement Plan The Company sponsors an Employee Retirement Plan, generally available to all employees, in accordance with Section 401 may may no June 30, 2017 2016.

Note 14 - Subsequent Event

Note 14 - Subsequent Event	12 Months Ended
	Jun. 30, 2017
Notes to Financial Statements
Subsequent Events [Text Block]	14 . Subsequent Event On July 7, 2017, 20% one $1.0 not 12 On September 13, 2017, No. 1 March 6, 2017, $5.0 $10.0 $10.0 In August 2017, June 30 December 31. 10 six December 31, 2017. 10 September 30, 2017.

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2017
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates Preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) and pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Estimates are used for, but not
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenues from the sale of the Company’s products and services are recognized when persuasive evidence of an arrangement exists, delivery has occurred (or services have been rendered), the price is fixed or determinable, and collectability is reasonably assured. The Company generally ships products F.O.B. shipping point. There is no The Company’s sales are generally through distributors. There is no not may not Revenue arrangements with multiple deliverables are divided into units of accounting if certain criteria are met, including whether the deliverable item(s) has (have) value to the customer on a stand-alone basis. Revenue for each unit of accounting is recognized as the unit of accounting is delivered. Arrangement consideration is allocated to each unit of accounting based upon the relative estimated selling prices of the separate units of accounting contained within an arrangement containing multiple deliverables. Estimated selling prices are determined using vendor specific objective evidence of value (VSOE), when available, or an estimate of selling price when VSOE is not Service revenue generated from contracts for providing maintenance of equipment is amortized over the life of the agreement. Revenue generated from storage contracts is deferred and recorded ratably over the life of the agreement, up to 21 Revenues are net of normal discounts. Shipping and handling fees billed to customers are included in net revenues, while the related costs are included in cost of revenues.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with a maturity of three may $46,000 $104,000 June 30, 2017 2016, not
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation The Company’s reporting currency is the US dollar. The functional currency of the Company’s subsidiaries in India is the Indian rupee (INR). Assets and liabilities are translated into US dollars at period end exchange rates. Revenue and expenses are translated at average rates of exchange prevailing during the periods presented. Cash flows are also translated at average exchange rates for the period, therefore, amounts reported on the consolidated statement of cash flows do not $1,000 $32,000 June 30, 2017 2016,
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block]	Goodwill, Intangible Assets and Impairment Assessments Goodwill represents the excess of the purchase price in a business combination over the fair value of net tangible and intangible assets acquired. Intangible assets that are not three ten not For goodwill and indefinite-lived intangible assets (clinical protocols), the carrying amounts are periodically reviewed for impairment (at least annually) and whenever events or changes in circumstances indicate that the carrying value of these assets may not ASC ”) 350, not 50 The Company performed a quantitative assessment as of April 1, 2017 June 30, 2017 no For the definite-lived intangible assets other than the covenants not no may not no no $310,000 not June 30, 2017
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments In accordance with ASC 820, Fair Value Measurements and Disclosures The guidance also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in valuing the asset or liability and are developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors that market participants would use in valuing the asset or liability. The guidance establishes three may Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Other observable inputs other than Level 1 not Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. The carrying values of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short duration. The fair value of the Company’s derivative obligation liability is classified as Level 3
Receivables, Policy [Policy Text Block]	Accounts Receivable and Allowance for Doubtful Accounts The Company’s receivables are recorded when billed and represent claims against third may
Inventory, Policy [Policy Text Block]	Inventories Inventories are stated at the lower of cost or market and include the cost of material, labor and manufacturing overhead. Cost is determined on the first first not third As a result, actual demand may may
Property, Plant and Equipment, Policy [Policy Text Block]	Equipment, Net Equipment consisting of office furniture, computer, machinery and equipment is recorded at cost less accumulated depreciation and amortization. Repairs and maintenance costs are expensed as incurred. Depreciation for office furniture, computer, machinery and equipment is computed under the straight-line method over the estimated useful lives. Leasehold improvements are amortized under the straight line method over their estimated useful lives or the remaining lease period, whichever is shorter. When equipment is sold or otherwise disposed of, the asset account and related accumulated depreciation account are relieved, and the impact of any resulting gain or loss is recognized within Other income and (expenses) in the consolidated statement of operations for the period.
Standard Product Warranty, Policy [Policy Text Block]	Warranty The Company provides for the estimated cost of product warranties at the time revenue is recognized. The Company’s warranty obligation is calculated based on estimated product failure rates, material usage and estimated service delivery costs incurred in correcting a product failure.
Debt, Policy [Policy Text Block]	Debt Issue Costs The Company amortizes debt issue costs to interest expense over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Debt Discount The Company amortizes debt discount over the life of the associated debt instrument, using the straight-line method which approximates the interest rate method. Such amortized cost is included with the other income (expense) in the accompanying consolidated statements of operations.
Derivatives, Policy [Policy Text Block]	Derivative Financial Instruments In connection with the sale of convertible debt and equity instruments, the Company may first
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company has three 9. Valuation and Amortization Method – The Company estimates the fair value of stock options granted using the Black-Scholes-Merton option-pricing formula. This fair value is then amortized on a straight-line basis over the requisite service periods of the awards, which is generally the vesting period. The formula does not not Expected Term – For options which the Company has limited available data, the expected term of the option is based on the simplified method. This simplified method averages an award’s vesting term and its contractual term. For all other options, the Company's expected term represents the period that the Company's stock-based awards are expected to be outstanding and was determined based on historical experience of similar awards, giving consideration to the contractual terms of the stock-based awards, vesting schedules and expectations of future employee behavior. Expected Volatility – Expected volatility is based on historical volatility. Historical volatility is computed using daily pricing observations for recent periods that corresponded to the expected term of the options. Expected Dividend – The Company has not not zero Risk-Free Interest Rate – The Company bases the risk-free interest rate used in the valuation method on the implied yield currently available on U.S. Treasury zero Estimated Forfeitures – When estimating forfeitures, the Company considers voluntary and involuntary termination behavior as well as analysis of actual option forfeitures.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Research and development costs, consisting of salaries and benefits, costs of clinical trials, costs of disposables, facility costs, contracted services and stock-based compensation from the engineering, regulatory, scientific and clinical affairs departments, that are useful in developing and clinically testing new products, services, processes or techniques, as well as expenses for activities that may no
Business Combinations Policy [Policy Text Block]	A cquired In-Process Research and Development Acquired in-process research and development (“clinical protocols”) that the Company acquires through business combinations represents the fair value assigned to incomplete research projects which, at the time of acquisition, have not first not not 2017 April 1, 2017. no
Legal Costs, Policy [Policy Text Block]	Patent Costs The costs incurred in connection with patent applications, in defending and maintaining intellectual property rights and litigation proceedings are expensed as incurred.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Credit Risk Currently, the Company primarily manufactures and sells cellular processing systems and thermodynamic devices principally to the blood and cellular component processing industry and performs ongoing evaluations of the credit worthiness of the Company’s customers. The Company believes that adequate provisions for uncollectible accounts have been made in the accompanying consolidated financial statements. To date, the Company has not
Segment Reporting, Policy [Policy Text Block]	Segment Reporting Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the Chief Operating Decision Maker (“CODM”), or decision making group, whose function is to allocate resources to and assess the performance of the operating segments. The Company has identified its chief executive officer and chief operating officer as the CODM. In determining its reportable segments, the Company considered the markets and the products or services provided to those markets. The Company has two The Clinical Development Division is devel op ing autologous (utilizing the patient’s own cells) stem cell-based therapeutics that address significant unmet medical needs for applications within the vascular, cardiology and orthopedic markets. The Device Division is a pioneer and market leader in the development and commercialization of automated technologies for c ell-based t herapeutics and bio-processing.
Income Tax, Policy [Policy Text Block]	Income Taxes The tax years 1999 2015 no no no The Company’s estimates of income taxes and the significant items resulting in the recognition of deferred tax assets and liabilities reflect the Company’s assessment of future tax consequences of transactions that have been reflected in the financial statements or tax returns for each taxing jurisdiction in which the Company operates. The Company bases the provision for income taxes on the Company’s current period results of operations, changes in deferred income tax assets and liabilities, income tax rates, and changes in estimates of uncertain tax positions in the jurisdictions in which the Company operates. The Company recognizes deferred tax assets and liabilities when there are temporary differences between the financial reporting basis and tax basis of assets and liabilities and for the expected benefits of using net operating loss and tax credit loss carryforwards. The Company establishes valuation allowances when necessary to reduce the carrying amount of deferred income tax assets to the amounts that the Company believes are more likely than not differences are expected to reverse. As the Company operates in more than one may Income tax consequences that arise in connection with a business combination include identifying the tax basis of assets and liabilities acquired and any contingencies associated with uncertain tax positions assumed or resulting from the business combination. Deferred tax assets and liabilities related to temporary differences of an acquired entity are recorded as of the date of the business combination and are based on the Company’s estimate of the appropriate tax basis that will be accepted by the various taxing authorities and its determination as to whether any of the acquired deferred tax liabilities could be a source of taxable income to realize the Company’s pre-existing deferred tax assets.
Earnings Per Share, Policy [Policy Text Block]	Net Loss per Share Net loss per share is computed by dividing the net loss to common stockholders by the weighted average number of common shares outstanding. The calculation of the basic and diluted earnings per share is the same for all periods presented, as the effect of the potential common stock equivalents is anti-dilutive due to the Company’s net loss position for all periods presented. Anti-dilutive securities consisted of the following at June 30: 2017 2016 Common stock equivalents of convertible debentures -- 3,676,471 Vested Series A warrants 404,412 404,412 Unvested Series A warrants 698,529 (1) 698,529 (1) Warrants – other 3,725,782 3,725,782 Stock options 397,388 104,378 Restricted stock units 59,694 63,566 Total 5,285,805 8,673,138 ( 1 The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second August 2015 February 2021.
New Accounting Pronouncements, Policy [Policy Text Block]	Recently Adopted Accounting Standards In June 2014, No. 2014 12, Compensation - Stock Compensation (Topic 718 Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period 2014 12 2014 12 July 1, 2016. 2014 12 2014 12 not Recently Issued Accounting Standards In July 2017, No. 2017 11, Earnings Per Share (Topic 260 480 815 2017 11 may no 2017 11 December 15, 2018, 2017 11 not 2017 11 In May 2017, No. 2017 09 718 2017 09 2017 09 718. December 15, 2017, In January 2017, 2017 04 2 December 15, 2019. January 1, 2017. not 2017 04 In March 2016, 2016 09, Compensation - Stock Compensation (Topic 718 2016 09 2016 09 December 15, 2016 not 2016 09 In March 2016, No. 2016 06, Derivatives and Hedging (Topic 815 2016 06” 2016 06 December 15, 2017, December 15, 2018. not In February 2016, 2016 02, “Leases (Topic 842 2016 02 2016 02 December 15, 2018 not 2016 02 In July 2015, No. 2015 11, Inventory: Simplifying the Measurement of Inventory not first December 15, 2016, In May 2014, 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 2014 09 605, 605 35, Revenue Recognition - Construction-Type and Production-Type Contracts 2014 09 2014 09 2014 09 2014 09 two first 2014 09 second 2014 09 2014 09 2019 2015 14, Revenue from Contracts with Customers (Topic 606 August 2015 one 2014 09 2015 14 not may There have been four 2014 09, 2016 08, Principal versus Agent Considerations (Reporting Revenue Gross Versus Net) March 2016 2014 09. 2016 10, Identifying Performance Obligations and Licensing April 2016, 2014 09 2016 12, Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients 2014 09 approach to adopt ASU 2014 09. 2016 20, Technical Corrections and Improvements to Topic 606, December 2016, 2014 09, four

Note 2 - Summary of Significa22

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2017 2016 Common stock equivalents of convertible debentures -- 3,676,471 Vested Series A warrants 404,412 404,412 Unvested Series A warrants 698,529 (1) 698,529 (1) Warrants – other 3,725,782 3,725,782 Stock options 397,388 104,378 Restricted stock units 59,694 63,566 Total 5,285,805 8,673,138

Note 3 - Intangible Assets (Tab

Note 3 - Intangible Assets (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Finite-Lived Intangible Assets [Table Text Block]	As of June 30, 2017 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulate d Amortization Impairment Net Trade names 7 $ 30,000 $ 14,000 $ 16,000 Licenses 7 482,000 233,000 249,000 Customer relationships 3 443,000 443,000 -- Device registration 7 90,000 60,000 30,000 Covenants not to compete 5 955,000 645,000 $ 310,000 -- Amortizable intangible assets 2,000,000 1,395,000 310,000 295,000 Clinical protocols 19,870,000 -- 19,870,000 Total $ 21,870,000 $ 1,395,000 $ 310,000 $ 20,165,000 As of June 30, 2016 Weighted Average Amortization Period (in Years) Gross Carrying Amount Accumulated Amortization Net Trade names 7 $ 29,000 $ 10,000 $ 19,000 Licenses 7 462,000 157,000 305,000 Customer relationships 3 424,000 335,000 89,000 Device registration 7 86,000 49,000 37,000 Covenants not to compete 5 955,000 454,000 501,000 Amortizable intangible assets 1,956,000 1,005,000 951,000 Clinical protocols 19,870,000 -- 19,870,000 Total $ 21,826,000 $ 1,005,000 $ 20,821,000
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Year Ended June 30, 2018 $ 81,000 2019 81,000 2020 81,000 2021 52,000 Total $ 295,000

Note 4 - Equipment (Tables)

Note 4 - Equipment (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	2017 2016 Estimated Useful Life (years) Machinery and equipment $ 5,772,000 $ 6,604,000 2.5 - 10 Computer and software 733,000 397,000 2 - 5 Office equipment 427,000 260,000 5 - 10 Leasehold improvements 227,000 149,000 Shorter of 5 years or remaining lease term Total equipment 7,159,000 7,410,000 Less accumulated depreciation and amortization (4,829,000 ) (4,448,000 ) Total equipment, net $ 2,330,000 $ 2,962,000

Note 6 - Convertible Debentur25

Note 6 - Convertible Debentures (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Extinguishment of Debt [Table Text Block]	Payment $ 7,500,000 Repayment of Thirty-Year debentures (5,500,000 ) Payment of accrued liquidated damages and interest (897,000 ) Loss on modification of Series A warrants (149,000 ) Cancellation of Series B derivative obligation (159,000 ) Loss on extinguishment of debt $ 795,000

Note 7 - Derivative Obligatio26

Note 7 - Derivative Obligations (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	Series A June 30, 2017 June 30, 2016 Market price of common stock $ 3.17 $ 2.93 Expected volatility 110 % 99 % Contractual term (years) 3.7 4.7 Discount rate 1.66 % 1.01 % Dividend rate 0 % 0 % Exercise price $ 8.00 $ 8.00
Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]	Balance at June 30, 2017 Level 1 Level 2 Level 3 Derivative obligation $ 730,000 $ - $ - $ 730,000 Balance at June 30, 2016 Level 1 Level 2 Level 3 Derivative obligation $ 670,000 $ - $ - $ 670,000
Derivative Instruments, Gain (Loss) [Table Text Block]	Amount Balance – July 1, 2016 $ 670,000 Change in fair value of derivative obligation 60,000 Balance – June 30, 2017 $ 730,000

Note 8 - Commitments and Cont27

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	2018 297,000 2019 279,000 2020 3,000 Total $ 579,000
Schedule of Product Warranty Liability [Table Text Block]	For years ended June 30, 2017 2016 Beginning balance $ 566,000 $ 627,000 Warranties issued during the period 120,000 97,000 Settlements made during the period (93,000 ) (287,000 ) Changes in liability for pre-existing warranties during the period (5,000 ) 129,000 Ending balance $ 588,000 $ 566,000

Note 9 - Stockholders' Equity (

Note 9 - Stockholders' Equity (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]	2017 2016 Number of Shares Weighted- Average Exercise Price Per Share Number of Shares Weighted - Average Exercise Price Per Share Beginning balance 4,828,723 $ 9.37 252,620 $ 44.18 Warrants granted -- 5,238,971 $ 9.83 Warrants exercised (cashless) -- (51,712 ) $ 13.60 Warrants expired/canceled -- (611,156 ) $ 17.21 Outstanding at June 30 4,828,723 $ 9.37 4,828,723 $ 9.37 Exercisable at June 30 4,130,192 $ 9.60 600,782 $ 19.02
Share-based Compensation, Stock Options, Activity [Table Text Block]	Number of Shares Weighted- Average Exercise Price Weighted- Average Remaining Contractual Life Aggregate Intrinsic Value Outstanding at June 30, 2016 104,378 $ 14.85 Granted 318,324 $ 2.98 Forfeited/cancelled (22,814 ) $ 6.39 Expired (2,500 ) $ 18.46 Exercised -- -- Outstanding at June 30, 2017 397,388 $ 5.80 6.2 $ 69,000 Vested and Expected to Vest at June 30, 2017 376,595 $ 5.94 6.2 $ 64,000 Exercisable at June 30, 2017 242,073 $ 7.38 5.5 $ 43,000
Non Vested Stock Options Activity [Table Text Block]	Non-vested Stock Options Weighted-Average Grant Date Fair Value Outstanding at June 30, 2016 43,107 $ 7.46 Granted 318,325 $ 2.16 Vested (185,019 ) $ 3.07 Forfeited (21,097 ) $ 3.31 Outstanding at June 30, 2017 155,316 $ 2.39
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2017 2016 Expected life (years) 4 5 Risk-free interest rate 1.3 % 1.5 % Expected volatility 102 % 80 % Dividend yield 0 % 0 %
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	2017 2016 Number of Shares Weighted- Average Grant Date Fair Value Number o f Shares Weighted- Average Grant Date Fair Value Balance at June 30 63,566 $ 14.96 72,589 $ 22.40 Granted 123,417 $ 4.55 10,000 $ 2.98 Vested (125,513 ) $ 9.47 (6,120 ) $ 28.94 Forfeited (1,776 ) $ 27.05 (12,903 ) $ 41.15 Outstanding at June 30 59,694 $ 4.62 63,566 $ 14.96

Note 10 - Concentrations (Table

Note 10 - Concentrations (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Schedules of Concentration of Risk, by Risk Factor [Table Text Block]	2017 2016 AXP $ 8,715,000 $ 6,932,000 BioArchive 3,318,000 2,465,000 Manual Disposables 1,195,000 1,507,000 Bone Marrow 745,000 459,000 Other 552,000 566,000 $ 14,525,000 $ 11,929,000
Schedule of Revenue from External Customers Attributed to Foreign Countries by Geographic Area [Table Text Block]	2017 2016 United States $ 6,675,000 $ 5,122,000 China 3,296,000 2,797,000 Asia – other 1,951,000 1,955,000 Europe 1,739,000 1,343,000 Other 864,000 712,000 $ 14,525,000 $ 11,929,000
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country [Table Text Block]	June 30, 2017 June 30, 2016 United States $ 1,559,000 $ 2,030,000 Costa Rica 322,000 367,000 India 261,000 279,000 All other countries 188,000 286,000 Total equipment, net $ 2,330,000 $ 2,962,000

Note 11 - Segment Reporting (Ta

Note 11 - Segment Reporting (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Reconciliation of Revenue from Segments to Consolidated [Table Text Block]	Year Ended June 30, 2017 Clinical Development Device Total Net revenues $ 492,000 $ 14,033,000 $ 14,525,000 Cost of revenues 466,000 8,220,000 8,686,000 Gross profit 26,000 5,813,000 5,839,000 Operating expenses 8,966,000 6,113,000 15,079,000 Operating profit (loss) $ (8,940,000 ) $ (300,000 ) $ (9,240,000 ) Depreciation and amortization $ 501,000 $ 329,000 $ 830,000 Stock-based compensation expense $ 970,000 $ 491,000 $ 1,461,000 Year Ended June 30, 2016 Clinical Development Device Total Net revenues $ 646,000 $ 11,283,000 $ 11,929,000 Cost of revenues 574,000 8,611,000 9,185,000 Gross profit 72,000 2,672,000 2,744,000 Operating expenses 8,312,000 5,297,000 13,609,000 Operating profit (loss) $ (8,240,000 ) $ (2,625,000 ) $ (10,865,000 ) Depreciation and amortization $ 644,000 $ 524,000 $ 1,168,000 Stock-based compensation expense $ 548,000 $ 194,000 $ 742,000

Note 12 - Income Taxes (Tables)

Note 12 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2017
Notes Tables
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2017 2016 Statutory federal income tax benefit $ (10,121,000 ) $ (6,300,000 ) Unbenefited net operating losses and credits 2,281,000 3,391,000 Disallowed financing costs 6,959,000 2,607,000 State and local taxes 88,000 69,000 Other 120,000 233,000 Total income tax benefit $ (673,000 ) $ --
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30, 2017 June 30, 2016 Deferred tax assets: Net operating loss carryforwards $ 43,687,000 $ 41,023,000 Income tax credit carryforwards 2,419,000 2,367,000 Stock compensation 1,047,000 874,000 Other 1,124,000 1,858,000 Total deferred tax assets 48,277,000 46,122,000 Deferred tax liabilities Indefinite lived intangible assets (6,968,000 ) (7,641,000 ) Depreciation and amortization (176,000 ) (230,000 ) Total deferred tax liabilities (7,144,000 ) (7,871,000 ) Valuation allowance (48,101,000 ) (45,892,000 ) Net deferred taxes $ (6,968,000 ) $ (7,641,000 )

Note 1 - Description of Busin32

Note 1 - Description of Business and Basis of Presentation (Details Textual)	Jul. 07, 2017USD ($)	Aug. 22, 2016USD ($)shares	Aug. 03, 2016USD ($)$ / sharesshares	Mar. 04, 2016shares	Sep. 20, 2017USD ($)	Jun. 30, 2017USD ($)shares	Jun. 30, 2016USD ($)shares	Sep. 13, 2017USD ($)	Mar. 06, 2017USD ($)	Jun. 30, 2015USD ($)
Common Stock, Shares Authorized | shares				350,000,000		350,000,000	350,000,000
Debt Conversion, Original Debt, Amount		$ 23,903,000
Debt Conversion, Converted Instrument, Shares Issued | shares		6,102,941
Stock Issued During Period, Shares, New Issues | shares			600,000
Shares Issued, Price Per Share | $ / shares			$ 4.10
Proceeds from Issuance of Common Stock			$ 2,092,000			$ 2,092,000	$ 2,463,000
Cash and Cash Equivalents, at Carrying Value						3,623,000	5,835,000			$ 3,357,000
Working Capital						6,658,000
Retained Earnings (Accumulated Deficit)						(185,357,000)	$ (156,262,000)
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Long-term Line of Credit						$ 3,500,000
Line of Credit Facility, Maximum Borrowing Capacity									$ 5,000,000
Subsequent Event [Member] | Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Proceeds from Lines of Credit					$ 1,500,000
Line of Credit Facility, Maximum Borrowing Capacity								$ 10,000,000
ThermoGenesis [Member] | SynGen [Member] | Subsequent Event [Member]
Percentage Of Common Stock Issued To Acquiree Shareholders	20.00%
Payments to Acquire Businesses, Gross	$ 1,000,000
Reverse Stock Split [Member]
Stockholders' Equity Note, Stock Split, Conversion Ratio				20

Note 2 - Summary of Significa33

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Maximum Period Of Agreement	21 years
Cash and Cash Equivalents, at Carrying Value	$ 3,623,000	$ 5,835,000	$ 3,357,000
Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax	1,000	$ 32,000
Finite-Lived Intangible Asset, Useful Life
Goodwill, Impairment Loss	0
Income Tax Examination, Penalties and Interest Accrued	0
Unrecognized Tax Benefits	$ 0	$ 0
Latest Tax Year [Member]
Open Tax Year	2,015
Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life	5 years	5 years
Impairment of Intangible Assets, Finite-lived	$ 310,000
Minimum [Member]
Finite-Lived Intangible Asset, Useful Life	3 years
Maximum [Member]
Finite-Lived Intangible Asset, Useful Life	10 years
INDIA
Cash and Cash Equivalents, at Carrying Value	$ 46,000	$ 104,000

Note 2 - Summary of Significa34

Note 2 - Summary of Significant Accounting Policies - Calculation for Basic and Diluted Earnings Per Share (Details) - shares		12 Months Ended
		Jun. 30, 2017	Jun. 30, 2016
Anti-dilutive securities (in shares)		5,285,805	8,673,138
Convertible Debt Securities [Member]
Anti-dilutive securities (in shares)			3,676,471
Vested Series A Warrants [Member]
Anti-dilutive securities (in shares)		404,412	404,412
Unvested Series A Warrants [Member]
Anti-dilutive securities (in shares)	[1]	698,529	698,529
Warrant, Other [Member]
Anti-dilutive securities (in shares)		3,725,782	3,725,782
Employee Stock Option [Member]
Anti-dilutive securities (in shares)		397,388	104,378
Restricted Stock Units (RSUs) [Member]
Anti-dilutive securities (in shares)		59,694	63,566
[1]	The unvested Series A warrants were subject to vesting based upon the amount of funds actually received by the Company in the second close of the August 2015 financing which never occurred. The warrants will remain outstanding but unvested until they expire in February 2021.

Note 3 - Intangible Assets (Det

Note 3 - Intangible Assets (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Impairment of Intangible Assets (Excluding Goodwill)	$ 310,000
Amortization of Intangible Assets	359,000	$ 438,000
Noncompete Agreements [Member]
Impairment of Intangible Assets (Excluding Goodwill)	$ 310,000

Note 3 - Intangible Assets - Su

Note 3 - Intangible Assets - Summary of Intangible Assets (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Net	$ 20,165,000	$ 20,821,000
Finite-Lived Intangible Asset, Useful Life
Gross Carrying Amount	21,870,000	$ 21,826,000
Accumulated Amortization	1,395,000	1,005,000
Impairment of intangible asset	310,000
Net	295,000	951,000
Gross Carrying Amount	$ 2,000,000	$ 1,956,000
Trade Names [Member]
Finite-Lived Intangible Asset, Useful Life	7 years	7 years
Accumulated Amortization	$ 14,000	$ 10,000
Impairment of intangible asset
Net	16,000	19,000
Gross Carrying Amount	$ 30,000	$ 29,000
Licensing Agreements [Member]
Finite-Lived Intangible Asset, Useful Life	7 years	7 years
Accumulated Amortization	$ 233,000	$ 157,000
Impairment of intangible asset
Net	249,000	305,000
Gross Carrying Amount	$ 482,000	$ 462,000
Customer Relationships [Member]
Finite-Lived Intangible Asset, Useful Life	3 years	3 years
Accumulated Amortization	$ 443,000	$ 335,000
Impairment of intangible asset
Net		89,000
Gross Carrying Amount	$ 443,000	$ 424,000
Device Registration [Member]
Finite-Lived Intangible Asset, Useful Life	7 years	7 years
Accumulated Amortization	$ 60,000	$ 49,000
Impairment of intangible asset
Net	30,000	37,000
Gross Carrying Amount	$ 90,000	$ 86,000
Noncompete Agreements [Member]
Finite-Lived Intangible Asset, Useful Life	5 years	5 years
Accumulated Amortization	$ 645,000	$ 454,000
Impairment of intangible asset	310,000
Net		501,000
Gross Carrying Amount	955,000	$ 955,000
Clinical Protocols [Member]
Finite-Lived Intangible Asset, Useful Life
Accumulated Amortization
Impairment of intangible asset
Net	19,870,000	19,870,000
Gross Carrying Amount	$ 19,870,000	$ 19,870,000

Note 3 - Intangible Assets - Fu

Note 3 - Intangible Assets - Future Amortization Expense (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
2,018	$ 81,000
2,019	81,000
2,020	81,000
2,021	52,000
Total	$ 295,000	$ 951,000

Note 4 - Equipment (Details Tex

Note 4 - Equipment (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Depreciation	$ 408,000	$ 630,000

Note 4 - Equipment - Summary of

Note 4 - Equipment - Summary of Property, Plant, and Equipment (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Property, Plant, and Equipment, Gross	$ 7,159,000	$ 7,410,000
Less accumulated depreciation and amortization	(4,829,000)	(4,448,000)
Property, Plant, and Equipment, Net	2,330,000	2,962,000
Machinery and Equipment [Member]
Property, Plant, and Equipment, Gross	$ 5,772,000	6,604,000
Machinery and Equipment [Member] | Minimum [Member]
Estimated Useful Life (Year)	2 years 182 days
Machinery and Equipment [Member] | Maximum [Member]
Estimated Useful Life (Year)	10 years
Computer and Software [Member]
Property, Plant, and Equipment, Gross	$ 733,000	397,000
Computer and Software [Member] | Minimum [Member]
Estimated Useful Life (Year)	2 years
Computer and Software [Member] | Maximum [Member]
Estimated Useful Life (Year)	5 years
Office Equipment [Member]
Property, Plant, and Equipment, Gross	$ 427,000	260,000
Office Equipment [Member] | Minimum [Member]
Estimated Useful Life (Year)	5 years
Office Equipment [Member] | Maximum [Member]
Estimated Useful Life (Year)	10 years
Leasehold Improvements [Member]
Leasehold Improvements, Estimated Useful Life	Shorter of 5 years or remaining lease term
Property, Plant, and Equipment, Gross	$ 227,000	$ 149,000

Note 5 - Related Party Transa40

Note 5 - Related Party Transactions (Details Textual) - USD ($)	Aug. 21, 2017	Mar. 06, 2017	Sep. 30, 2017	Jun. 30, 2017	Jun. 30, 2017	Jun. 30, 2016	Sep. 13, 2017
Interest Expense					$ 10,668,000	$ 1,864,000
Boyalife Group Ltd. [Member]
Due to Related Parties				$ 606,000	606,000
Revenue from Related Parties					308,000
Accounts Receivable, Related Parties				308,000	308,000
Boyalife Investment Fund II, Inc. [Member] | Subsequent Event [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount							$ 10,000,000
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Amount of Unsecured Debt Per Advance		$ 500,000
Proceeds from Long-term Lines of Credit		$ 1,500,000		$ 2,000,000
Debt Instrument, Interest Rate, Stated Percentage		22.00%
Debt Instrument, Convertible, Percentage of Conversion Price		90.00%
Debt Instrument, Number of Trading Days Prior to the Maturity Date		10 days
Debt Instrument, Maximum Number of Shares Issued Upon Conversion, Percent		19.99%
Interest Expense					$ 122,000
Line of Credit Facility, Maximum Borrowing Capacity		$ 5,000,000
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member] | Subsequent Event [Member]
Line of Credit Facility, Maximum Borrowing Capacity							$ 10,000,000
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member] | Scenario, Forecast [Member]
Proceeds from Long-term Lines of Credit			$ 1,500,000
Boyalife W.S.N. [Member] | Subsequent Event [Member]
Distributor Agreement Term	3 years
Distributor Agreement, Renewal Term	2 years

Note 6 - Convertible Debentur41

Note 6 - Convertible Debentures (Details Textual) - USD ($)	Aug. 22, 2016	Aug. 03, 2016	Feb. 29, 2016	Feb. 16, 2016	Aug. 31, 2015	Feb. 29, 2016	Dec. 31, 2015	Jun. 30, 2017	Jun. 30, 2016
Gain (Loss) on Extinguishment of Debt									$ (795,000)
Debt Conversion, Converted Instrument, Shares Issued	6,102,941
Amortization of Debt Discount (Premium)								9,851,000	6,127,000
Amortization of Debt Issuance Costs								160,000	800,000
Stock Issued During Period, Shares, New Issues		600,000
Stock Issued During Period, Value, New Issues								2,092,000	2,464,000
Approval for Grant in Amount for Clinical Trial					$ 10,000,000
Proceeds from Convertible Debt									18,000,000
Registration Payment Arrangement, Gains and Losses									(1,100,000)
Derivative, Gain (Loss) on Derivative, Net								$ (60,000)	$ 3,395,000
Warrants Issued in Connection with Convertible Debentures [Member]
Warrant Expiration Period						5 years
Number of Warrants, Percentage of Shares Issued or to Be Issued						80.00%
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			3,529,412			3,529,412
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 8			$ 8
Series B Warrant [Member]
Warrant Expiration Period					18 years
Class of Warrant or Right, Cancelled During Period,Value				$ 159,000
Class of Warrant or Right, Outstanding					222,427
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					606,618
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 13.60
Shares Issued for Cashless Exercise of Warrants				125,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding					404,412				404,412
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 8			$ 8
Fair Value Assumptions, Expected Volatility Rate			91.00%
Fair Value Inputs, Discount Rate			1.20%
Fair Value Assumptions, Expected Term			5 years
Fair Value Assumptions, Expected Dividend Rate			0.00%
Series A Warrant [Member] | Other Expense [Member]
Derivative, Gain (Loss) on Derivative, Net									$ (149,000)
Common Stock [Member]
Stock Issued During Period, Shares, New Issues								600,000	735,294
Stock Issued During Period, Value, New Issues								$ 1,000	$ 1,000
Boyalife Investment Inc. [Member]
Stock Issued During Period, Shares, New Issues						735,294
Sale of Stock, Price Per Share			$ 3.40			$ 3.40
Stock Issued During Period, Value, New Issues						$ 2,500,000
Debt Instrument, Face Amount			$ 12,500,000			$ 12,500,000
Convertible Debt [Member] | Boyalife Investment Inc. [Member]
Debt Conversion, Original Debt Principal, Amount	$ 12,500,000
Debt Conversion, Original Debt Interest, Amount	8,250,000
Additional Interest Expense, Debt	3,153,000
Amortization of Debt Discount (Premium)	9,538,000
Amortization of Debt Issuance Costs	155,000
Convertible Debt [Member] | Boyalife Investment Inc. [Member] | Common Stock [Member]
Debt Conversion, Original Debt Interest, Amount	$ 8,250,000
Debt Conversion, Converted Instrument, Shares Issued	6,102,941
Debt Conversion, Convertible Shares			3,676,471			3,676,471
Convertible Debt [Member] | Boyalife Investment Inc. [Member] | Common Stock [Member] | Conversion of Interest [Member]
Debt Conversion, Converted Instrument, Shares Issued	2,426,470
Debt Conversion, Converted Instrument, Amount	$ 11,403,000
Convertible Debt [Member] | Boyalife Investment Inc. [Member]
Gross Proceeds from Financing Transaction						$ 15,000,000
Thirty-Year Debentures [Member]
Warrant Expiration Period					5 years 182 days
Class of Warrant or Right, Cancelled During Period,Value									159,000
Gain (Loss) on Extinguishment of Debt									(795,000)
Amortization of Debt Discount (Premium)				$ 4,648,000					4,720,000
Amortization of Debt Issuance Costs				$ 765,000					777,000
Gross Proceeds from Convertible Debt					$ 5,500,000				5,500,000
Potential Proceed from Issuance of Convertible Debt					$ 15,000,000
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					1,102,942
Proceeds from Convertible Debt					$ 4,720,000
Convertible Debt					0
Debt Instrument, Unamortized Discount					$ 4,720,000
Debt Instrument, Term					30 years
Registration Payment Arrangement, Gains and Losses									1,100,000
Registration Payment							$ 220,000
Repayments of Debt			$ 7,500,000						$ 7,500,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 13.60
Thirty-Year Debentures [Member] | Series B Warrant [Member]
Residual Fair Value of Warrants					$ 897,000
Thirty-Year Debentures [Member] | Series A Warrant [Member]
Residual Fair Value of Warrants					3,385,000
Payment After Approval of Authorities [Member]
Potential Proceed from Issuance of Convertible Debt					9,500,000
Thirty-Year Debentures, Beneficial Conversion Feature [Member]
Debt Instrument, Convertible, Beneficial Conversion Feature					$ 438,000

Note 6 - Convertible Debentur42

Note 6 - Convertible Debentures - Schedule of Extinguishment of Debt (Details) - USD ($)	Feb. 29, 2016	Aug. 31, 2015	Jun. 30, 2017	Jun. 30, 2016
Loss on modification of Series A warrants				$ 149,000
Loss on extinguishment of debt				795,000
Thirty-Year Debentures [Member]
Repayments of Debt	$ 7,500,000			7,500,000
Repayment of Thirty-Year debentures		$ (5,500,000)		(5,500,000)
Payment of accrued liquidated damages and interest				(897,000)
Loss on modification of Series A warrants				(149,000)
Cancellation of Series B derivative obligation				(159,000)
Loss on extinguishment of debt				$ 795,000

Note 7 - Derivative Obligatio43

Note 7 - Derivative Obligations (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Aug. 31, 2015
Derivative, Gain (Loss) on Derivative, Net	$ (60,000)	$ 3,395,000
Series A Warrant [Member]
Class of Warrant or Right, Outstanding		404,412	404,412

Note 7 - Derivative Obligatio44

Note 7 - Derivative Obligations - Fair Value Assumptions (Details) - Series A Warrant [Member] - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Market price of common stock (in dollars per share)	$ 3.17	$ 2.93
Expected volatility	110.00%	99.00%
Contractual term (years) (Year)	3 years 255 days	4 years 255 days
Discount rate	1.66%	1.01%
Dividend rate	0.00%	0.00%
Exercise price (in dollars per share)	$ 8	$ 8

Note 7 - Derivative Obligatio45

Note 7 - Derivative Obligations - Fair Value Hierarchy (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Derivative obligations	$ 730,000	$ 670,000
Fair Value, Inputs, Level 1 [Member]
Derivative obligations
Fair Value, Inputs, Level 2 [Member]
Derivative obligations
Fair Value, Inputs, Level 3 [Member]
Derivative obligations	$ 730,000	$ 670,000

Note 7 - Derivative Obligatio46

Note 7 - Derivative Obligations - Change In Fair Value of Derivative Liabilities (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Balance	$ 670,000
Change in fair value of derivative obligation	60,000	$ (3,395,000)
Balance	$ 730,000	$ 670,000

Note 8 - Commitments and Cont47

Note 8 - Commitments and Contingencies (Details Textual) - USD ($)	May 04, 2017	Jun. 30, 2017	Jun. 30, 2016
Operating Leases, Rent Expense, Net		$ 291,000	$ 657,000
Short Term Investment Minimum		$ 2,000,000
Payment Terms, Severance Compensation		1 year
Minimum [Member]
Period Of Warranty On Products		1 year
Maximum [Member]
Period Of Warranty On Products		2 years
Potential Severance Cost for Chief Operating Officer [Member]
Loss Contingency, Estimate of Possible Loss		$ 320,000
Litigation Related to Strategic Advisory Services [Member]
Loss Contingency, Damages Sought, Value	$ 1,000,000
Loss Contingency Accrual		$ 0

Note 8 - Commitments and Cont48

Note 8 - Commitments and Contingencies - Future Minimum Lease Payments for Non-cancelable Operating Lease (Details)	Jun. 30, 2017USD ($)
2,018	$ 297,000
2,019	279,000
2,020	3,000
Total	$ 579,000

Note 8 - Commitments and Cont49

Note 8 - Commitments and Contingencies - Changes In Product Liability Included In Accrued Liabilities (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Beginning balance	$ 566,000	$ 627,000
Warranties issued during the period	120,000	97,000
Settlements made during the period	(93,000)	(287,000)
Changes in liability for pre-existing warranties during the period	(5,000)	129,000
Ending balance	$ 588,000	$ 566,000

Note 9 - Stockholders' Equity50

Note 9 - Stockholders' Equity (Details Textual)

Jul. 01, 2017shares

Feb. 24, 2017$ / sharesshares

Dec. 16, 2016$ / sharesshares

Aug. 22, 2016USD ($)shares

Aug. 03, 2016USD ($)$ / sharesshares

Jul. 26, 2016USD ($)shares

Jul. 07, 2016USD ($)$ / sharesshares

Jul. 31, 2016shares

Mar. 31, 2017USD ($)shares

Dec. 31, 2016USD ($)shares

Jun. 30, 2017USD ($)$ / sharesshares

Jun. 30, 2016USD ($)$ / sharesshares

May 05, 2017shares

Debt Conversion, Converted Instrument, Shares Issued

6,102,941

Stock Issued During Period, Shares, New Issues

600,000

Shares Issued, Price Per Share | $ / shares

$ 4.10

Payments of Stock Issuance Costs | $

$ 369,000

Proceeds from Issuance of Common Stock | $

$ 2,092,000

$ 2,092,000

$ 2,463,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

0

0

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 2.16

$ 5.75

Allocated Share-based Compensation Expense | $

$ 1,461,000

$ 742,000

Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period

0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

318,324

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 2.98

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $

$ 275,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

1 year 182 days

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value | $

$ 572,000

$ 354,000

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

397,388

104,378

Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

123,417

10,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Share-based Awards Other than Options | $

$ 43,000

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

210 days

Shares Paid for Tax Withholding for Share Based Compensation

145

1,300

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

125,513

6,120

Former Chief Executive Officer [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number

72,496

Former Chief Executive Officer [Member] | Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number

79,720

Former Chief Financial Officer [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number

16,248

Former Chief Financial Officer [Member] | Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number

15,914

Former Chief Executive Officer and Former Chief Financial Officer [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Pre-Modification of Agreement

90 days

Chief Operating Officer [Member] | Employee Stock Option [Member]

Number Of Installments

4

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

25,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 2.89

Chief Operating Officer [Member] | Restricted Stock Units (RSUs) [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period

25,000

Chief Operating Officer [Member] | Restricted Stock Units (RSUs) [Member] | Share-based Compensation Award, Tranche One [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Chief Operating Officer [Member] | Restricted Stock Units (RSUs) [Member] | Share-based Compensation Award, Tranche Two [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Chief Operating Officer [Member] | Restricted Stock Units (RSUs) [Member] | Share-based Compensation Award, Tranche Three [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Chief Operating Officer [Member] | Restricted Stock Units (RSUs) [Member] | Share-based Compensation Award, Tranche Four [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage

25.00%

Interim Chief Executive Officer [Member] | Employee Stock Option [Member]

Number Of Installments

5

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

7 years

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures

50,000

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 2.91

General and Administrative Expense [Member]

Share-based Compensation Arrangement by Share-based Payment Award Accelerated Compensation Cost | $

$ 94,000

$ 539,000

Short Term Plan [Member]

Shares Paid for Tax Withholding for Share Based Compensation

46,879

Share-based Compensation Arrangement by Share-based Payment Award, Aggregate Amount of Issuable Cash Award | $

$ 276,000

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

104,000

Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period

98,417

118,288

Share-based Compensation Arrangement by Share-based Payment Award, Amount of Cash Award Issued in Period | $

$ 266,000

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

51,636

Short Term Plan [Member] | Subsequent Event [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period

46,781

Amended 2016 Plan [Member

Share-based Compensation Arrangement by Share-based Payment Award, Accumulated Shares Issued

254,224

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

600,000

Plan 2012 [Member]

Options Prices In Terms Of Fair Market Value

100.00%

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

10 years

Common Stock, Capital Shares Reserved for Future Issuance

194

Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number

134,164

Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized

25,000

The 2016 Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

156,100

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares

$ 2.86

The 2016 Plan [Member] | Employee Stock Option [Member]

Share-based Compensation Arrangement by Share-based Payment Award, Award Ratable Vesting Period

180 days

Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period

3 years

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

7 years

Common Stock [Member]

Stock Issued During Period, Shares, New Issues

600,000

735,294

Convertible Debt [Member] | Boyalife Investment Inc. [Member]

Debt Conversion, Original Debt Principal, Amount | $

$ 12,500,000

Debt Conversion, Original Debt Interest, Amount | $

8,250,000

Convertible Debt [Member] | Boyalife Investment Inc. [Member] | Common Stock [Member]

Debt Conversion, Original Debt Interest, Amount | $

$ 8,250,000

Debt Conversion, Converted Instrument, Shares Issued

6,102,941

Note 9 - Stockholders' Equity -

Note 9 - Stockholders' Equity - Warrant Activity (Details) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Beginning balance (in shares)	4,828,723	252,620
Beginning balance (in dollars per share)	$ 9.37	$ 44.18
Warrants granted (in shares)		5,238,971
Warrants granted (in dollars per share)		$ 9.83
Warrants exercised (cashless) (in shares)		(51,712)
Warrants exercised (cashless) (in dollars per share)		$ 13.60
Warrants expired/canceled (in shares)		(611,156)
Warrants expired/canceled (in dollars per share)		$ 17.21
Ending balance (in shares)	4,828,723	4,828,723
Ending balance (in dollars per share)	$ 9.37	$ 9.37
Exercisable at June 30 (in shares)	4,130,192	600,782
Exercisable at June 30 (in dollars per share)	$ 9.60	$ 19.02

Note 9 - Stockholders' Equity52

Note 9 - Stockholders' Equity - Option Activity for Stock Option Plans (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Granted, weighted average exercise price, options (in dollars per share)	$ 2.16	$ 5.75
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0	0
Employee Stock Option [Member]
Outstanding, options (in shares)	104,378
Outstanding, weighted average exercise price, options (in dollars per share)	$ 14.85
Granted, options (in shares)	318,324
Granted, weighted average exercise price, options (in dollars per share)	$ 2.98
Forfeited/cancelled (in shares)	(22,814)
Forfeited/cancelled (in dollars per share)	$ 6.39
Expired, options (in shares)	(2,500)
Expired, weighted average exercise price, options (in dollars per share)	$ 18.46
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period	0
Exercised, weighted average exercise price, options (in dollars per share)	$ 0
Outstanding, options (in shares)	397,388	104,378
Outstanding, weighted average exercise price, options (in dollars per share)	$ 5.80	$ 14.85
Outstanding, weighted average remaining contractual life, options (Year)	6 years 73 days
Outstanding, aggregate intrinsic value, options	$ 69,000
Vested and Expected to Vest, options (in shares)	376,595
Vested and Expected to Vest, weighted average exercise price, options (in dollars per share)	$ 5.94
Vested and Expected to Vest, weighted average remaining contractual life, options (Year)	6 years 73 days
Vested and Expected to Vest, aggregate intrinsic value, options	$ 64,000
Exercisable, options (in shares)	242,073
Exercisable, weighted average exercise price, options (in dollars per share)	$ 7.38
Exercisable, weighted average remaining contractual life, options (Year)	5 years 182 days
Exercisable, aggregate intrinsic value, options	$ 43,000

Note 9 - Stockholders' Equity53

Note 9 - Stockholders' Equity - Non-vested Stock Options Activity (Details) - Non-vested Stock Options [Member]	12 Months Ended
	Jun. 30, 2017$ / sharesshares
Outstanding, options (in shares) | shares	43,107
Outstanding at June 30, 2016 (in dollars per share) | $ / shares	$ 7.46
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | shares	318,325
Granted (in dollars per share) | $ / shares	$ 2.16
Vested (in shares) | shares	(185,019)
Vested (in dollars per share) | $ / shares	$ 3.07
Forfeited/cancelled (in shares) | shares	(21,097)
Forfeited (in dollars per share) | $ / shares	$ 3.31
Outstanding, options (in shares) | shares	155,316
Outstanding at June 30, 2017 (in dollars per share) | $ / shares	$ 2.39

Note 9 - Stockholders' Equity54

Note 9 - Stockholders' Equity - Schedule of Assumptions (Details)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Expected life (years) (Year)	4 years	5 years
Risk-free interest rate	1.30%	1.50%
Expected volatility	102.00%	80.00%
Dividend yield	0.00%	0.00%

Note 9 - Stockholders' Equity55

Note 9 - Stockholders' Equity - Restricted Stock Activity Granted to Employees (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Balance, Number of Shares (in shares)	63,566	72,589
Balance, Weighted Average Grant Date Fair Value, (in dollars per share)	$ 14.96	$ 22.40
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period	123,417	10,000
Granted, Weighted Average Grant Date Fair Value (in dollars per share)	$ 4.55	$ 2.98
Vested, Weighted Average Grant Date Fair Value (in dollars per share)	$ 9.47	$ 28.94
Vested, Number of Shares (in shares)	(125,513)	(6,120)
Forfeited, Number of Shares (in shares)	(1,776)	(12,903)
Forfeited, Weighted Average Grant Date Fair Value (in dollars per share)	$ 27.05	$ 41.15
Outstanding, Number of Shares (in shares)	59,694	63,566
Outstanding, Weighted Average Grant Date Fair Value, (in dollars per share)	$ 4.62	$ 14.96

Note 10 - Concentrations (Detai

Note 10 - Concentrations (Details Textual)	12 Months Ended
	Jun. 30, 2017USD ($)	Jun. 30, 2016USD ($)
Accounts Receivable, Net, Current	$ 3,701,000	$ 3,169,000
Revenue, Net	$ 14,525,000	$ 11,929,000
Number of Suppliers	2	2
Supplier Concentration Risk [Member] | Cost of Goods, Total [Member] | Supplier 1 [Member]
Concentration Risk, Percentage	64.00%	65.00%
Supplier Concentration Risk [Member] | Cost of Goods, Total [Member] | Supplier 2 [Member]
Concentration Risk, Percentage	20.00%	21.00%
Distributor 1 [Member]
Accounts Receivable, Net, Current	$ 1,388,000	$ 901,000
Revenue, Net	$ 2,842,000	$ 2,797,000
Distributor 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	36.00%	28.00%
Distributor 1 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	20.00%	23.00%
Customer 1 [Member]
Accounts Receivable, Net, Current	$ 259,000	$ 620,000
Revenue, Net	$ 3,263,000	$ 2,475,000
Customer 1 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	7.00%	19.00%
Customer 1 [Member] | Customer Concentration Risk [Member] | Sales Revenue, Net [Member]
Concentration Risk, Percentage	22.00%	21.00%
Distributor 2 [Member]
Accounts Receivable, Net, Current	$ 304,000	$ 320,000
Distributor 2 [Member] | Customer Concentration Risk [Member] | Accounts Receivable [Member]
Concentration Risk, Percentage	8.00%	10.00%

Note 10 - Concentrations - Reve

Note 10 - Concentrations - Revenues by Product Platform (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Revenue, Net	$ 14,525,000	$ 11,929,000
Product Concentration Risk [Member] | AXP [Member]
Revenue, Net	8,715,000	6,932,000
Product Concentration Risk [Member] | BioArchive [Member]
Revenue, Net	3,318,000	2,465,000
Product Concentration Risk [Member] | Manual Disposables [Member]
Revenue, Net	1,195,000	1,507,000
Product Concentration Risk [Member] | Bone Marrow [Member]
Revenue, Net	745,000	459,000
Product Concentration Risk [Member] | Other Segments [Member]
Revenue, Net	$ 552,000	$ 566,000

Note 10 - Concentrations - Sale

Note 10 - Concentrations - Sales to Customers (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Revenue, Net	$ 14,525,000	$ 11,929,000
Geographic Concentration Risk [Member] | UNITED STATES
Revenue, Net	6,675,000	5,122,000
Geographic Concentration Risk [Member] | CHINA
Revenue, Net	3,296,000	2,797,000
Geographic Concentration Risk [Member] | Asia - Other [Member]
Revenue, Net	1,951,000	1,955,000
Geographic Concentration Risk [Member] | Europe [Member]
Revenue, Net	1,739,000	1,343,000
Geographic Concentration Risk [Member] | All Other Countries [Member]
Revenue, Net	$ 864,000	$ 712,000

Note 10 - Concentrations - Summ

Note 10 - Concentrations - Summary of Net Equipment by Geographic Area (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Property, Plant, and Equipment, Net	$ 2,330,000	$ 2,962,000
Geographic Concentration Risk [Member] | UNITED STATES
Property, Plant, and Equipment, Net	1,559,000	2,030,000
Geographic Concentration Risk [Member] | COSTA RICA
Property, Plant, and Equipment, Net	322,000	367,000
Geographic Concentration Risk [Member] | INDIA
Property, Plant, and Equipment, Net	261,000	279,000
Geographic Concentration Risk [Member] | All Other Countries [Member]
Property, Plant, and Equipment, Net	$ 188,000	$ 286,000

Note 11 - Segment Reporting (De

Note 11 - Segment Reporting (Details Textual)	12 Months Ended
	Jun. 30, 2017
Number of Reportable Segments	2

Note 11 - Segment Reporting - S

Note 11 - Segment Reporting - Summary of Operating Results by Reportable Segments (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Operating expenses	$ 15,079,000	$ 13,609,000
Operating profit (loss)	(9,240,000)	(10,865,000)
Depreciation and amortization	830,000	1,168,000
Stock-based compensation expense	1,461,000	742,000
Net revenues	14,525,000	11,929,000
Cost of revenues	8,686,000	9,185,000
Gross profit	5,839,000	2,744,000
Clinical Development [Member]
Operating expenses	8,966,000
Operating profit (loss)	(8,940,000)
Depreciation and amortization	501,000
Stock-based compensation expense	970,000
Net revenues	492,000
Cost of revenues	466,000
Gross profit	26,000
Clinical Protocols [Member]
Operating expenses		8,312,000
Operating profit (loss)		(8,240,000)
Depreciation and amortization		644,000
Stock-based compensation expense		548,000
Net revenues		646,000
Cost of revenues		574,000
Gross profit		72,000
Device [Member]
Operating expenses	6,113,000
Operating profit (loss)	(300,000)
Depreciation and amortization	329,000
Stock-based compensation expense	491,000
Net revenues	14,033,000
Cost of revenues	8,220,000
Gross profit	$ 5,813,000
Device Registration [Member]
Operating expenses		5,297,000
Operating profit (loss)		(2,625,000)
Depreciation and amortization		524,000
Stock-based compensation expense		194,000
Net revenues		11,283,000
Cost of revenues		8,611,000
Gross profit		$ 2,672,000

Note 12 - Income Taxes (Details

Note 12 - Income Taxes (Details Textual) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015
Income (Loss) from Continuing Operations before Income Taxes, Domestic	$ 29,005,000	$ (17,789,000)
Income (Loss) from Continuing Operations before Income Taxes, Foreign	$ (763,000)	(799,000)
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	34.00%
Deferred Income Tax Expense (Benefit)	$ (673,000)
Deferred Income Tax (Benefit) Due to Prior Years State Rate Changes	(559,000)	$ (157,000)	$ (402,000)
Tax Credit Carryforward, Amount	1,456,000
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	2,209,000
Tax Benefits Related To Stock Options Included In Valuation Allowance	215,000
Domestic Tax Authority [Member]
Operating Loss Carryforwards	118,956,000
Tax Credit Carryforward, Amount	1,458,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 42,922,000

Note 12 - Income Taxes - Reconc

Note 12 - Income Taxes - Reconciliation of Federal Income Tax Attributable to Operations to Income Tax Expense (Benefit) (Details) - USD ($)	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Statutory federal income tax benefit	$ (10,121,000)	$ (6,300,000)
Unbenefited net operating losses and credits	2,281,000	3,391,000
Disallowed financing costs	6,959,000	2,607,000
State and local taxes	88,000	69,000
Other	120,000	233,000
Total income tax benefit	$ (673,000)

Note 12 - Income Taxes - Compon

Note 12 - Income Taxes - Components of Company's Deferred Tax Assets and Liabilities for Federal and State Income Taxes (Details) - USD ($)	Jun. 30, 2017	Jun. 30, 2016
Deferred tax assets:
Net operating loss carryforwards	$ 43,687,000	$ 41,023,000
Income tax credit carryforwards	2,419,000	2,367,000
Stock compensation	1,047,000	874,000
Other	1,124,000	1,858,000
Total deferred tax assets	48,277,000	46,122,000
Deferred tax liabilities
Indefinite lived intangible assets	(6,968,000)	(7,641,000)
Depreciation and amortization	(176,000)	(230,000)
Total deferred tax liabilities	(7,144,000)	(7,871,000)
Valuation allowance	(48,101,000)	(45,892,000)
Net deferred taxes	$ (6,968,000)	$ (7,641,000)

Note 13 - Employee Retirement65

Note 13 - Employee Retirement Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2017	Jun. 30, 2016
Defined Benefit Plan, Plan Assets, Contributions by Employer	$ 0	$ 0

Note 14 - Subsequent Event (Det

Note 14 - Subsequent Event (Details Textual) - USD ($)	Jul. 07, 2017	Sep. 13, 2017	Mar. 06, 2017
Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity			$ 5,000,000
Subsequent Event [Member] | Boyalife Investment Fund II, Inc. [Member] | Convertible Promissory Note [Member]
Debt Instrument, Face Amount		$ 10,000,000
Subsequent Event [Member] | Boyalife Investment Fund II, Inc. [Member] | Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity		$ 10,000,000
ThermoGenesis [Member] | SynGen [Member] | Subsequent Event [Member]
Percentage Of Common Stock Issued To Acquiree Shareholders	20.00%
Payments to Acquire Businesses, Gross	$ 1,000,000